HIMS Stock Overview
Operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Hims & Hers Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$28.14 |
| 52 Week High | US$72.98 |
| 52 Week Low | US$11.20 |
| Beta | 1.65 |
| 1 Month Change | -24.03% |
| 3 Month Change | -8.84% |
| 1 Year Change | 129.34% |
| 3 Year Change | 538.10% |
| 5 Year Change | 182.25% |
| Change since IPO | 187.14% |
Recent News & Updates
Recent updates
Hims & Hers: Look Past Near-Term GLP-1 Risks, This Is A Great Dip To Buy
Apr 23With A 29% Price Drop For Hims & Hers Health, Inc. (NYSE:HIMS) You'll Still Get What You Pay For
Mar 24
Hims & Hers Has Superstar Potential, But It Will Take A Lot To Get There
Mar 20Hims & Hers' Fall From Grace Is Warranted - Still No Margin Of Safety
Mar 03Hims & Hers: Why This Q4 Earnings Dip Is A Buying Opportunity
Feb 25Hims & Hers Q4 Preview: Is The Super Bowl Ad Worth $5B In Market Cap? (Rating Downgrade)
Feb 19Hims & Hers Health: Explosive Growth Potential Ahead
Feb 11Market Participants Recognise Hims & Hers Health, Inc.'s (NYSE:HIMS) Revenues Pushing Shares 46% Higher
Feb 04Hims & Hers: Potential Risks Ahead, But Shorting May Be Premature
Jan 29Hims & Hers Health: The Market Is Likely Wrong
Jan 19Don't Buy Hims & Hers Stock If You Want Better Than Mediocre Returns
Jan 09Hims & Hers: Ready For Liftoff In 2025
Jan 02Hims & Hers: FDA Ruling May Close Compounded GLP-1 Drug 'Loophole', It Was Fun While It Lasted
Dec 19Hims & Hers: Look At What Matters Most
Dec 12Hims & Hers: The Show Must Go On
Dec 05Hims & Hers: Driving Growth In Wellness
Nov 29Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 44% Share Price Surge
Nov 26Hims & Hers Health: The Amazon Curse Is Being Overstated
Nov 15Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
Nov 05HIMS: GLP-1 Is Just The Beginning
Oct 17Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward
Oct 03Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce
Oct 01Hims & Hers Is Unbelievably Cheap And Profitable: Buy Now
Sep 24
Expanding Into Personalized Weight Management And AI Integration Spurs Market Leadership
Sep 05 Expansion into weight management and GLP-1 compounds addresses a massive potential market, suggesting diversification and possible revenue growth.Hims & Hers Health Post Q2 Earnings - Compounded GLP-1 Ploy Faces New Threats (Rating Downgrade)
Aug 27Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade
Aug 20Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Aug 11Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage
Aug 07Hims & Hers: The Thesis Goes Far Beyond GLP-1
Jul 18Hims & Hers: Buy The Dip To Catch The Next Rip
Jun 24Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge
Jun 19Hims & Hers: The Undervalued Gem Poised For Growth
Jun 18Beyond The Marketing Machine: Why Hims & Hers Stock Might Be Vulnerable
Jun 10Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment
May 31Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead
May 21Hims & Hers Health: An Unforced Error
May 06Shareholder Returns
| HIMS | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 3.3% | -2.5% | 4.1% |
| 1Y | 129.3% | -9.7% | 7.9% |
Return vs Industry: HIMS exceeded the US Healthcare industry which returned -9.7% over the past year.
Return vs Market: HIMS exceeded the US Market which returned 7.9% over the past year.
Price Volatility
| HIMS volatility | |
|---|---|
| HIMS Average Weekly Movement | 18.9% |
| Healthcare Industry Average Movement | 7.4% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: HIMS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: HIMS's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 1,637 | Andrew Dudum | www.hims.com |
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care.
Hims & Hers Health, Inc. Fundamentals Summary
| HIMS fundamental statistics | |
|---|---|
| Market cap | US$5.93b |
| Earnings (TTM) | US$126.04m |
| Revenue (TTM) | US$1.48b |
49.6x
P/E Ratio4.2x
P/S RatioIs HIMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HIMS income statement (TTM) | |
|---|---|
| Revenue | US$1.48b |
| Cost of Revenue | US$303.38m |
| Gross Profit | US$1.17b |
| Other Expenses | US$1.05b |
| Earnings | US$126.04m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 05, 2025
| Earnings per share (EPS) | 0.57 |
| Gross Margin | 79.45% |
| Net Profit Margin | 8.54% |
| Debt/Equity Ratio | 0% |
How did HIMS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/24 16:57 |
| End of Day Share Price | 2025/04/24 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hims & Hers Health, Inc. is covered by 20 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vikram Kesavabhotla | Baird |
| Allen Lutz | BofA Global Research |
| Allen Lutz | BofA Global Research |